Slide 1: Q4 2024 Earnings Call
Q4 2024 EARNINGS CALL OFER HAVIV | PRESIDENT & CEO March 06, 2025
Slide 2: Forward-looking statements
This presentation contains "forward-looking statements" relating to future events, and Evogene Ltd. (the “Company”), may from time to time make other statements, regarding our outlook or expectations for future financial or operating results and/or other matters regarding or affecting us that are co
Slide 3: Agenda
Earnings Call Q4 2024 AGENDA Nir Nimrodi, New Chairman Financial & Business Highlights Evogene Overview Subsidiaries’ 2025 Targets Q&A 3 CEO Update / By Ofer Haviv CFO Update / By Yaron Eldad
Slide 4: CEO Update: New Chairman Nir Nimrodi
4 4 CEO UPDATE Mr. Nir Nimrodi has served as Special Advisor to the Evogene board since 2020, and from September 2022 as a board member. Mr. Nimrodi brings 25 years of diverse international experience in both start-ups and large global businesses in the life science, pharmaceutical, and biotechnolog
Slide 5: Agenda
Earnings Call Q4 2024 AGENDA Nir Nimrodi, New Chairman Financial & Business Highlights Evogene Overview Subsidiaries’ 2025 Targets Q&A 5 CEO Update / By Ofer Haviv CFO Update / By Yaron Eldad
Slide 6: CEO Update: Financial Highlights (Revenues)
6 6 CEO UPDATE Financial Highlights: In the year 2024, total revenues reached approximately $8.5 million compared to $5.6 million in the year 2023. The increase in revenues in year 2024, is mainly due to increase in AgPlenus' revenues from its collaboration with Bayer and an increase in Casterra’s s
Slide 7: CEO Update: Financial Highlights (R&D and G&A)
7 7 CEO UPDATE Financial Highlights: In the year 2024, total R&D expenses were approximately $16.6 million compared to $20.8 million in the year 2023. In Q4 of 2024, total R&D expenses were approximately $3.4 million compared to $5.5 million in Q4 2023. These decreases are mainly due to the end of C
Slide 8: CEO Update: Business Highlights 2024 to date
8 8 CEO UPDATE Business Highlights 2024 to date: Evogene Oct. 2024, collaboration with Google Cloud to pioneer generative AI foundation model for novel small molecule design. Casterra During 2024, Casterra delivered to its partner ~215 tons of castor seeds, ~76 tons in Q4 2024. In February 2025 Cast
Slide 9: Business Highlights 2024 to date: Lavie Bio and AgPlenus
Business Highlights 2024 to date: Lavie Bio Feb. 2024, new collaboration agreement with Syngenta to discover and develop novel bio-insecticides. July 2024, ICL and Lavie Bio achieved a significant milestone in their collaboration, developing yield-increasing bio-stimulants for row crops under extrem
Slide 10: Agenda
Earnings Call Q4 2024 AGENDA Nir Nimrodi, New Chairman Financial & Business Highlights Evogene Overview Subsidiaries’ 2025 Targets Q&A 10 CEO Update / By Ofer Haviv CFO Update / By Yaron Eldad
Slide 11: Our Vision and Mission
OUR VISION PIONEER GROUNDBREAKING LIFE-SCIENCE PRODUCTS ROOTED IN MICROBES, SMALL MOLECULES, AND GENOMICS DECODING BIOLOGY 11 OUR MISSION WE MERGE LIFE-SCIENCE WITH BIG DATA AND CUTTING-EDGE AI TECHNOLOGIES TO EFFECTIVELY DISCOVER AND OPTIMIZE BREAKTHROUGH LIFE-SCIENCE BASED PRODUCTS
Slide 12: Discovery & Optimization
DISCOVERY & OPTIMIZATION WE DIRECT AND ACCELERATE LIFE-SCIENCE PRODUCT through 3 dedicated AI tech-engines MICROBES GENETIC ELEMENTS SMALL MOLECULES The Result: Promising candidates addressing multiple development challenges towards successful life-science-based products. PROBABILITY OF SUCCESS TIME
Slide 13: A World of Opportunities for Our AI Tech Engines
13 SMALL MOLECULES GENETIC ELEMENTS MICROBES A WORLD OF OPPORTUNITIES FOR OUR AI TECH ENGINES AGRICULTURE & FOOD PHARMA & WELLNESS OTHER INDUSTRIES Improvedcrops Alternativefood Medical Cannabis Genetherapy Diagnostics & precisionmedicine Celltherapy Bio fuel Fragrances Natural foodcoloring Novelenz
Slide 14: Business Strategy
14 BUSINESS STRATEGY Capture the value of our AI tech-engines through diverse collaborative partnerships to accelerate life-science product development Partnering with experts in specific fields complements our technology, enabling groundbreaking innovations and financial gains for Evogene. EVOGENE
Slide 15: Licensing & Collaboration: Current Status
Aquaculture Licensing Collaboration Improved crops Crop protection Pharmaceuticals Microbials for crops Therapeutic microbials 15 LICENSING & COLLABORATION | CURRENT STATUS Food-Tech AGRICULTURE & FOOD PHARMA & WELLNESS OTHER INDUSTRIES AGRICULTURE & FOOD PHARMA & WELLNESS OTHER INDUSTRIES AGRICULTU
Slide 16: Commercial & Financial Partners
16 Group COMMERCIAL & FINANCIAL PARTNERS Investment & Collaboration Collaboration Investment & Collaboration Collaboration Collaboration Investment Collaboration Collaboration Collaboration Collaboration Collaboration
Slide 17: Looking into 2025-2026
17 17 LOOKING INTO 2025-2026 Evogene Focus on enhancing ChemPass AI tech-engine’s competitive advantage for the pharma market segment (ex. - building foundation model with Google Cloud). Engage in collaborations with bio-tech and academia for small-molecule drug discovery, utilizing ChemPass AI. Con
Slide 18: Drug Development Based on Small Molecules
SMALL MOLECULES GENETIC ELEMENTS MICROBES AGRICULTURE & FOOD PHARMA & WELLNESS OTHER INDUSTRIES Improvedcrops Alternativefood Medical Cannabis Genetherapy Diagnostics & precisionmedicine Celltherapy Bio fuel Fragrances Natural foodcoloring Novelenzymes AGRICULTURE & FOOD PHARMA & WELLNESS OTHER INDU
Slide 19: Why Pharma?
The Challenge: Discovering the right small molecule is like finding a needle in a haystack. The Rewards: A solution offers the potential for significant financial impact. The AI Revolution: AI enables the discovery and optimization of small molecule candidates, addressing multiple development requir
Slide 20: Multi-Million Agreements with Global Pharma
MULTI-MILLION AGREEMENTS WITH GLOBAL PHARMA 20
Slide 21: Why Evogene?
WHY EVOGENE? Multidisciplinary Expertise Integrating chemistry, biology, and AI for optimized drug discovery Collaborative PartnershipProven ability to work with partners, to translate computational predictions into real-world drug candidates AI-First ApproachInternal capabilities to develop proprie
Slide 22: Discussions with Potential Partners
22 AUSTRALIA CANADA SOUTH KOREA ISRAEL GERMANY UK DISCUSSIONS WITH POTENTIAL PARTNERS USA
Slide 23: Agenda
Earnings Call Q4 2024 AGENDA Nir Nimrodi, New Chairman Financial & Business Highlights Evogene Overview Subsidiaries’ 2025 Targets Q&A 23 CEO Update / By Ofer Haviv CFO Update / By Yaron Eldad
Slide 24: Casterra: Main Targets for 2025
24 Casterra focuses on developing integrated solutions for large-scale castor bean farming, utilizing GeneRator AI tech-engine Powered by Main targets for 2025 Increase castor seeds revenue in Africa with initial sales in Brazil and additional territories. Initiate POC trials for grain farming for o
Slide 25: Lavie Bio: Main Targets for 2025
25 Lavie Bio, a global leader in developing next generation ag-biological products, leveraging MicroBoost AI tech-engine Main targets for 2025 Engage in a new collaboration agreement for fungicides (LAV311, LAV321). Increase Yalos® revenue with initial sales in soybean. Achieve R&D milestones in ICL
Slide 26: AgPlenus: Main Targets for 2025
AgPlenus specializes in developing novel and sustainable crop protection products, utilizing Evogene’s ChemPass AI tech-engine Powered by 26 Main targets for 2025 Achieve 2nd milestone in Corteva collaboration agreement. Execute Bayer herbicide collaboration according to workplan. Discover and advan
Slide 27: Biomica: Main Targets for 2025
27 Biomica specializes in developing microbiome-based therapeutics for human health, utilizing Evogene's MicroBoost AI tech-engine Powered by Main targets for 2025 Complete Phase 1 study in oncology program; obtain full results and additional supporting clinical data. Submit IND application to the U
Slide 28: Agenda
Earnings Call Q4 2024 AGENDA Nir Nimrodi, New Chairman Financial & Business Highlights Evogene Overview Subsidiaries’ 2025 Targets Q&A 28 CEO Update / By Ofer Haviv CFO Update / By Yaron Eldad
Slide 29: CFO Update: Consolidated Statements of Financial Position
WCFO UPDATE CONSOLIDATED STATEMENTS OF FINANCIAL POSITION evOgene USS. dollars in thousands ‘CURRENT ASSETS: Cash and cash equivalents Short-term bank deposits Trade receivables Other receivables and prepaid expenses Deferred expenses related to issuance of warrants Inventories LONG-TERM ASSETS: Lon
Slide 30: CFO Update: Liabilities and Shareholders' Equity
WCFO UPDATE December 31, December 31, 2024 2023 CURRENT LIABILITIES: Trade payables Ss 128 $1,785 Employees and payroll accruals 1,869 2,537 Lease liability 589 853 Liabilities in respect of government grants 323 388 Deferred revenues and other advances 360 362 ‘Warrants and pre-funded warrants liab
Slide 31: CFO Update: Evogene Financial Performance 2024 and Q4 2024
CFO UPDATE Evogene Financial Performance 2024 and Q4 2024 31
Slide 32: Agenda
Earnings Call Q4 2024 AGENDA Nir Nimrodi, New Chairman Financial & Business Highlights Evogene Overview Subsidiaries’ 2025 Targets Q&A 32 CEO Update / By Ofer Haviv CFO Update / By Yaron Eldad
Slide 33: Thank You
} THANK YOU 5)